Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer - Contacts and Locations

Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00132054

Locations


Japan
	Gunma Cancer Center
	Gunma, Japan, 373-0828
	Kitano Hospital
	Osaka, Japan, 530-8480
	Kyoto University Hospital
	Kyoto, Japan, 606-8501
	Osaka Police Hospital
	Osaka City, Japan, 543-0035
	National Hospital Organization - Osaka National Hospital
	Osaka, Japan, 591-8555
	Osaka Kosei Nenkin Hospital
	Osaka, Japan, 553-0003
	National Hospital Organization - Dohoku National Hospital
	Hokkaido, Japan, 070-0901

Sponsors and Collaborators

Japan Multinational Trial Organization

Investigators


Study Chair:	Tadashi Mio, MD	Kyoto University